A Single-Dose Live-Attenuated Zika Virus Vaccine with Controlled Infection Rounds that Protects against Vertical Transmission

Xuping Xie, Dieudonné B. Kum, Hongjie Xia, Huanle Luo, Chao Shan, Jing Zou, Antonio E. Muruato, Daniele B.A. Medeiros, Bruno T.D. Nunes, Kai Dallmeier, Shannan Rossi, Scott Weaver, Johan Neyts, Tian Wang, Pedro F.C. Vasconcelos, Pei-Yong Shi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Zika virus (ZIKV) infection of the mother during pregnancy causes devastating Zika congenital syndrome in the offspring. A ZIKV vaccine with optimal safety and immunogenicity for use in pregnant women is critically needed. Toward this goal, we have developed a single-dose live-attenuated vaccine candidate that infects cells with controlled, limited infection rounds. The vaccine contains a 9-amino-acid deletion in the viral capsid protein and replicates to titers of > 106 focus-forming units (FFU)/mL in cells expressing the full-length capsid protein. Immunization of A129 mice with one dose (105 FFU) did not produce viremia, but elicited protective immunity that completely prevented viremia, morbidity, and mortality after challenge with an epidemic ZIKV strain (106 PFU). A single-dose vaccination also fully prevented infection of pregnant mice and maternal-to-fetal transmission. Intracranial injection of the vaccine (104 FFU) to 1-day-old mice did not cause any disease or death, underscoring the safety of this vaccine candidate. A ZIKV vaccine for use in pregnant women requires an optimal balance between safety and immunogenicity. Xie et al. developed a live-attenuated vaccine candidate that can infect cells with controlled, limited infection rounds. A single-dose immunization of the vaccine prevents vertical transmission of ZIKV in pregnant mice.

Original languageEnglish (US)
Pages (from-to)487-499.e5
JournalCell Host and Microbe
Volume24
Issue number4
DOIs
StatePublished - Oct 10 2018

Fingerprint

Vaccines
Infection
Attenuated Vaccines
Viremia
Capsid Proteins
Safety
Pregnant Women
Immunization
Mothers
Viral Proteins
Zika Virus
Immunity
Vaccination
Morbidity
Amino Acids
Pregnancy
Injections
Mortality

Keywords

  • flavivirus capsid
  • vaccine
  • Zika virus

ASJC Scopus subject areas

  • Parasitology
  • Microbiology
  • Virology

Cite this

A Single-Dose Live-Attenuated Zika Virus Vaccine with Controlled Infection Rounds that Protects against Vertical Transmission. / Xie, Xuping; Kum, Dieudonné B.; Xia, Hongjie; Luo, Huanle; Shan, Chao; Zou, Jing; Muruato, Antonio E.; Medeiros, Daniele B.A.; Nunes, Bruno T.D.; Dallmeier, Kai; Rossi, Shannan; Weaver, Scott; Neyts, Johan; Wang, Tian; Vasconcelos, Pedro F.C.; Shi, Pei-Yong.

In: Cell Host and Microbe, Vol. 24, No. 4, 10.10.2018, p. 487-499.e5.

Research output: Contribution to journalArticle

Xie, Xuping ; Kum, Dieudonné B. ; Xia, Hongjie ; Luo, Huanle ; Shan, Chao ; Zou, Jing ; Muruato, Antonio E. ; Medeiros, Daniele B.A. ; Nunes, Bruno T.D. ; Dallmeier, Kai ; Rossi, Shannan ; Weaver, Scott ; Neyts, Johan ; Wang, Tian ; Vasconcelos, Pedro F.C. ; Shi, Pei-Yong. / A Single-Dose Live-Attenuated Zika Virus Vaccine with Controlled Infection Rounds that Protects against Vertical Transmission. In: Cell Host and Microbe. 2018 ; Vol. 24, No. 4. pp. 487-499.e5.
@article{b3e1f5c398b5400f86d7ffbde1c87bc0,
title = "A Single-Dose Live-Attenuated Zika Virus Vaccine with Controlled Infection Rounds that Protects against Vertical Transmission",
abstract = "Zika virus (ZIKV) infection of the mother during pregnancy causes devastating Zika congenital syndrome in the offspring. A ZIKV vaccine with optimal safety and immunogenicity for use in pregnant women is critically needed. Toward this goal, we have developed a single-dose live-attenuated vaccine candidate that infects cells with controlled, limited infection rounds. The vaccine contains a 9-amino-acid deletion in the viral capsid protein and replicates to titers of > 106 focus-forming units (FFU)/mL in cells expressing the full-length capsid protein. Immunization of A129 mice with one dose (105 FFU) did not produce viremia, but elicited protective immunity that completely prevented viremia, morbidity, and mortality after challenge with an epidemic ZIKV strain (106 PFU). A single-dose vaccination also fully prevented infection of pregnant mice and maternal-to-fetal transmission. Intracranial injection of the vaccine (104 FFU) to 1-day-old mice did not cause any disease or death, underscoring the safety of this vaccine candidate. A ZIKV vaccine for use in pregnant women requires an optimal balance between safety and immunogenicity. Xie et al. developed a live-attenuated vaccine candidate that can infect cells with controlled, limited infection rounds. A single-dose immunization of the vaccine prevents vertical transmission of ZIKV in pregnant mice.",
keywords = "flavivirus capsid, vaccine, Zika virus",
author = "Xuping Xie and Kum, {Dieudonn{\'e} B.} and Hongjie Xia and Huanle Luo and Chao Shan and Jing Zou and Muruato, {Antonio E.} and Medeiros, {Daniele B.A.} and Nunes, {Bruno T.D.} and Kai Dallmeier and Shannan Rossi and Scott Weaver and Johan Neyts and Tian Wang and Vasconcelos, {Pedro F.C.} and Pei-Yong Shi",
year = "2018",
month = "10",
day = "10",
doi = "10.1016/j.chom.2018.09.008",
language = "English (US)",
volume = "24",
pages = "487--499.e5",
journal = "Cell Host and Microbe",
issn = "1931-3128",
publisher = "Cell Press",
number = "4",

}

TY - JOUR

T1 - A Single-Dose Live-Attenuated Zika Virus Vaccine with Controlled Infection Rounds that Protects against Vertical Transmission

AU - Xie, Xuping

AU - Kum, Dieudonné B.

AU - Xia, Hongjie

AU - Luo, Huanle

AU - Shan, Chao

AU - Zou, Jing

AU - Muruato, Antonio E.

AU - Medeiros, Daniele B.A.

AU - Nunes, Bruno T.D.

AU - Dallmeier, Kai

AU - Rossi, Shannan

AU - Weaver, Scott

AU - Neyts, Johan

AU - Wang, Tian

AU - Vasconcelos, Pedro F.C.

AU - Shi, Pei-Yong

PY - 2018/10/10

Y1 - 2018/10/10

N2 - Zika virus (ZIKV) infection of the mother during pregnancy causes devastating Zika congenital syndrome in the offspring. A ZIKV vaccine with optimal safety and immunogenicity for use in pregnant women is critically needed. Toward this goal, we have developed a single-dose live-attenuated vaccine candidate that infects cells with controlled, limited infection rounds. The vaccine contains a 9-amino-acid deletion in the viral capsid protein and replicates to titers of > 106 focus-forming units (FFU)/mL in cells expressing the full-length capsid protein. Immunization of A129 mice with one dose (105 FFU) did not produce viremia, but elicited protective immunity that completely prevented viremia, morbidity, and mortality after challenge with an epidemic ZIKV strain (106 PFU). A single-dose vaccination also fully prevented infection of pregnant mice and maternal-to-fetal transmission. Intracranial injection of the vaccine (104 FFU) to 1-day-old mice did not cause any disease or death, underscoring the safety of this vaccine candidate. A ZIKV vaccine for use in pregnant women requires an optimal balance between safety and immunogenicity. Xie et al. developed a live-attenuated vaccine candidate that can infect cells with controlled, limited infection rounds. A single-dose immunization of the vaccine prevents vertical transmission of ZIKV in pregnant mice.

AB - Zika virus (ZIKV) infection of the mother during pregnancy causes devastating Zika congenital syndrome in the offspring. A ZIKV vaccine with optimal safety and immunogenicity for use in pregnant women is critically needed. Toward this goal, we have developed a single-dose live-attenuated vaccine candidate that infects cells with controlled, limited infection rounds. The vaccine contains a 9-amino-acid deletion in the viral capsid protein and replicates to titers of > 106 focus-forming units (FFU)/mL in cells expressing the full-length capsid protein. Immunization of A129 mice with one dose (105 FFU) did not produce viremia, but elicited protective immunity that completely prevented viremia, morbidity, and mortality after challenge with an epidemic ZIKV strain (106 PFU). A single-dose vaccination also fully prevented infection of pregnant mice and maternal-to-fetal transmission. Intracranial injection of the vaccine (104 FFU) to 1-day-old mice did not cause any disease or death, underscoring the safety of this vaccine candidate. A ZIKV vaccine for use in pregnant women requires an optimal balance between safety and immunogenicity. Xie et al. developed a live-attenuated vaccine candidate that can infect cells with controlled, limited infection rounds. A single-dose immunization of the vaccine prevents vertical transmission of ZIKV in pregnant mice.

KW - flavivirus capsid

KW - vaccine

KW - Zika virus

UR - http://www.scopus.com/inward/record.url?scp=85054030294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054030294&partnerID=8YFLogxK

U2 - 10.1016/j.chom.2018.09.008

DO - 10.1016/j.chom.2018.09.008

M3 - Article

VL - 24

SP - 487-499.e5

JO - Cell Host and Microbe

JF - Cell Host and Microbe

SN - 1931-3128

IS - 4

ER -